Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/176718
Title: HDL-related biomarkers are robust predictors of survival in patients with chronic liver failure
Author: Trieb, Markus
Rainer, Florian
Stadlbauer, Vanessa
Douschan, Philipp
Horvath, Angela
Binder, Lukas
Trakaki, Athina
Knuplez, Eva
Scharnagl, Hubert
Stojakovic, Tatjana
Heinemann, Ákos
Mandorfer, Mattias
Paternostro, Rafael
Reiberger, Thomas
Pitarch Abaigar, Carla
Amorós, Àlex
Gerbes, Alexander L.
Caraceni, Paolo
Alessandria, Carlo
Moreau, Richard
Clària i Enrich, Joan
Marsche, Gunther
Stauber Rudolf E.
Keywords: Insuficiència hepàtica
Marcadors bioquímics
Liver failure
Biochemical markers
Issue Date: 1-Mar-2020
Publisher: Elsevier
Abstract: Background & Aims: High-density lipoprotein cholesterol (HDL-C) levels are reduced in patients with chronic liver disease and inversely correlate with disease severity. During acute conditions such as sepsis, HDL-C levels decrease rapidly and HDL particles undergo profound changes in their composition and function. We aimed to determine whether indices of HDL quantity and quality associate with progression and survival in patients with advanced liver disease. Methods: HDL-related biomarkers were studied in 508 patients with compensated or decompensated cirrhosis (including acute-on-chronic liver failure [ACLF]) and 40 age- and gender-matched controls. Specifically, we studied levels of HDL-C, its subclasses HDL2-C and HDL3-C, and apolipoprotein A1 (apoA-I), as well as HDL cholesterol efflux capacity as a metric of HDL functionality. Results: Baseline levels of HDL-C and apoA-I were significantly lower in patients with stable cirrhosis compared to controls and were further decreased in patients with acute decompensation (AD) and ACLF. In stable cirrhosis (n = 228), both HDL-C and apoA-I predicted the development of liver-related complications independently of model for end-stage liver disease (MELD) score. In patients with AD, with or without ACLF (n = 280), both HDL-C and apoA-I were MELD-independent predictors of 90-day mortality. On ROC analysis, both HDL-C and apoA-I had high diagnostic accuracy for 90-day mortality in patients with AD (AUROCs of 0.79 and 0.80, respectively, similar to that of MELD 0.81). On Kaplan-Meier analysis, HDL-C <17 mg/dl and apoA-I <50 mg/dl indicated poor short-term survival. The prognostic accuracy of HDL-C was validated in a large external validation cohort of 985 patients with portal hypertension due to advanced chronic liver disease (AUROCs HDL-C: 0.81 vs. MELD: 0.77). Conclusion: HDL-related biomarkers are robust predictors of disease progression and survival in chronic liver failure.
Note: Reproducció del document publicat a: https://doi.org/10.1016/j.jhep.2020.01.026
It is part of: Journal of Hepatology, 2020, vol. 73, num. 1, p. 113-120
URI: http://hdl.handle.net/2445/176718
Related resource: https://doi.org/10.1016/j.jhep.2020.01.026
ISSN: 0168-8278
Appears in Collections:Articles publicats en revistes (Biomedicina)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Files in This Item:
File Description SizeFormat 
699931.pdf726.69 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons